Website
Now part of www.zoetis.com
Nexvet – has been acquired Zoetis. View Press Release
Nexvet (NASDAQ:NVET) is a global clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals developing and commercializing novel biologic therapies , including “100% species-specific” products derived from their PETization™ technology.
PETization™ is designed to rapidly create monoclonal antibodies (“mAbs”) that are recognized as “self” a patient’s immune system, a property we refer to as 100% species-specificity.
